Read the paper at https://doi.org/10.1177/17407745211012438
Assessing the external validity of the VALIDATE-SWEDEHEART trial
The VALIDATE-SWEDEHEART trial was a registry-based randomized trial comparing bivalirudin and heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention. It showed no differences in mortality at 30 or 180 days. This study examines how well the trial population results may generalize to the population of all screened patients with fulfilled inclusion criteria in regard to mortality at 30 and 180 days.
Latest news
23 May 2019 | News
Development and Validation of a Novel Risk Score for In-Hospital Major Bleeding in Acute Myocardial Infarction:-The SWEDEHEART Score.
Bleeding risk stratification in acute coronary syndrome is of highest clinical interest but current risk scores have limitations. We sought to develop and validate a new in-hospita...
19 Dec 2019 | News
Biobank linked to SWEDEHEART quality registry-routine blood sample collection opens new opportunities for cardiovascular research.
High-quality biobanking within routine health services, through the use of existing health-care practices and infrastructure, with respect to safety and integrity of patients in li...
7 Jul 2020 | News
Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial
Elderly patients with acute myocardial infarction undergoing percutaneous coronary intervention are at increased risk of both ischemic and bleeding complications. The optimal antic...